Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Five Major Advancements in Thoracic Surgery Over the Past 50 Years.

World journal of surgery·2026
Same author

A propensity-matched analysis of the impact of early and late percutaneous endoscopic gastrostomy tube placement among patients with significant comorbidities.

Surgery·2026
Same author

One step backward, two steps forward: esophageal diversion and the staged reconstruction of esophageal catastrophe.

Journal of thoracic disease·2026
Same author

County-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care.

JAMA network open·2026
Same author

Clearing the Smoke on Smoking Cessation.

Journal of the American College of Surgeons·2026
Same author

The surgical management of mediastinal paragangliomas: A modern series reflecting true collaboration between cardiac and thoracic surgeons.

JTCVS open·2026

相关实验视频

Updated: Jun 9, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

治疗模式和EGFR突变非小细胞肺癌患者的临床结果在奥西默提尼布的进展后.

Nathaniel D Robinson1, Maureen E Canavan1, Peter L Zhan1

  • 1Yale University School of Medicine, New Haven, CT.

Clinical lung cancer
|October 27, 2024
PubMed
概括

对于在奥西默蒂尼布治疗中进展的晚期EGFR突变NSCLC患者,在第二线治疗中继续使用奥西默蒂尼布和化疗,与其他疗法相比,显著改善了无进展和整体存活率.

关键词:
获得的电阻 获得的电阻化疗 化疗是一种化学疗法.在NSCLCLC中,我们可以看到.非小细胞肺癌是非小细胞肺癌.有针对性的治疗.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

相关实验视频

Last Updated: Jun 9, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

科学领域:

  • 在瘤学瘤学.
  • 医学研究 医学研究

背景情况:

  • 在奥西默提尼布进展后,晚期EGFR突变非小细胞肺癌 (NSCLC) 的最佳二线治疗方法尚不清楚.
  • 目前用于后续治疗的实践模式是多样化的.

研究的目的:

  • 评估EGFR突变NSCLC患者的治疗模式,以评估第一线 osimertinib 后进展的患者.
  • 评估不同二线疗法与患者生存结果之间的关联.

主要方法:

  • 追溯队列研究,使用非识别的全国电子健康记录数据库.
  • 分析包括538名患者,在一线 osimertinib 治疗后有可用的二线治疗数据.

主要成果:

  • 第二线治疗方案各不相同,通常包括化疗 (65%),免疫检查点抑制剂 (37%) 和EGFR氨酸激酶抑制剂 (44%).
  • 在333名患者 (性能状况0-2) 中,继续使用奥西默蒂尼布与化疗显示出较高的无进展生存率 (10.1个月与5.9个月) 和总生存率 (17.0个月与12.8个月) 与单独使用化疗相比.
  • 这种益处在EGFR外基因19缺失的患者中最为显著.

结论:

  • 在EGFR突变的NSCLC中,Osimertinib在进展后采用了广泛的二线治疗.
  • 继续使用奥西默蒂尼布与化疗结合,表明无进展和整体存活率有所改善.